Canandaigua National Trust Co of Florida Buys New Stake in Thermo Fisher Scientific Inc. $TMO

Canandaigua National Trust Co of Florida bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,104 shares of the medical research company’s stock, valued at approximately $745,000.

Other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $15,501,867,000. Corient Private Wealth LP purchased a new stake in Thermo Fisher Scientific in the second quarter worth $382,547,000. Bank of New York Mellon Corp bought a new position in Thermo Fisher Scientific in the second quarter worth $1,974,561,000. Bank of America Corp DE bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $1,952,930,000. Finally, Auto Owners Insurance Co grew its position in shares of Thermo Fisher Scientific by 57,845.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock worth $1,406,844,000 after buying an additional 2,423,706 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph Holmes sold 420 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Lisa Britt sold 11,440 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the transaction, the vice president owned 14,784 shares in the company, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 73,768 shares of company stock worth $44,122,820. Company insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

TMO has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $720.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, September 25th. HSBC raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 1st. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 28th. Piper Sandler assumed coverage on Thermo Fisher Scientific in a report on Wednesday, September 9th. They issued an “overweight” rating on the stock. Finally, Wells Fargo & Company downgraded Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a report on Wednesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $633.13.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded up $4.39 during midday trading on Wednesday, reaching $660.97. 1,825,338 shares of the company’s stock traded hands, compared to its average volume of 2,251,859. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $694.33. The company has a market cap of $244.39 billion, a price-to-earnings ratio of 35.56, a P/E/G ratio of 2.83 and a beta of 0.87. The stock has a 50 day moving average of $622.56 and a 200 day moving average of $537.94.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period last year, the company earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Constructive outlook from investors: ClearBridge Investments highlighted Thermo Fisher’s strong third-quarter guidance, broadening demand across end markets and multi-year growth potential. The company’s innovation, acquisitions and diversified exposure to pharmaceutical, biotechnology and research customers are viewed as supporting its long-term outlook. Thermo Fisher Scientific Strong Q3 Guidance and Broadening Demand Support Multi-Year Outlook
• Positive Sentiment: Expanded drug-development capabilities: At CPHI Milan, Thermo Fisher announced new and expanded manufacturing, clinical and drug-development solutions, including OSD Express. These offerings could improve customer efficiency and strengthen the company’s position as pharmaceutical companies outsource increasingly complex development and commercialization work. Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities
• Positive Sentiment: New clinical-research contract: Thermo Fisher’s PPD business will support Quantum BioPharma’s Phase 2 multiple-sclerosis trial. The agreement adds to Thermo Fisher’s clinical-research backlog and demonstrates demand for its contract research services, although the financial impact was not disclosed. Quantum BioPharma Signs Contract with Thermo Fisher Scientific
• Neutral Sentiment: Industry trends remain favorable: A market report projects continued growth in cell-based assays and high-content screening, driven by 3D assays, automation and immuno-oncology research. Thermo Fisher is listed among major participants, but the report does not announce company-specific financial results or contracts. Cell-Based Assay and High Content Screening Market Report
• Negative Sentiment: Recent volatility and valuation concerns: TMO recently fell sharply after hours and in the prior session, erasing roughly $10 billion in market value, likely reflecting profit-taking after reaching a new one-year high. Analysts also note macroeconomic and currency risks. With the stock trading at a premium earnings multiple, further gains may depend on continued execution and guidance upgrades. Is This the Right Time to Add TMO Stock to Your Portfolio?

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.